App-Quantinova.ai

Antibodies to CNTN1/CASPR1 complex in a relapsing-remitting immune-mediated neuropathy: An indolent, atypical history, expanding the phenotype.

Rob Durcan - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Peripheral neuropathy

N/A

Ataluren Delays Loss of Ambulation and Decline in Pulmonary Function in Patients with Nonsense Mutation Duchenne Muscular Dystrophy

Craig Mcnald - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Duchenne muscular dystrophy

Deflazacort

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study

Heinz Wiendl - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Cladribine

Description of clinical symptoms of a large international cohort of patients with valosin-containing-protein related disease

Marta Caballero-�vila - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Development and Usability Testing of a Patient-based Digital Tool to Understand Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Tjalf Ziemssen - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Effectiveness and Tolerability of Perampanel in Epilepsy Patients Treated in Routine Clinical Practice: a Global Pooled Analysis Study

Wendyl DSouza - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Epilepsy

Perampanel

Efficacy and Safety of Adjunctive Perampanel for Myoclonic and Absence Seizures: Post Hoc Pooled Analysis of Adult, Adolescent, and Pediatric Patients in Studies 332, 311, and 232

Christian Brandt - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Epilepsy

Perampanel

Evaluation of rAAV2/2-ND4 Gene Therapy Efficacy in Leber Hereditary Optic Neuropathy Using an External Control Group of Untreated Patients

Nancy Newman - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Leber optic atrophy

Lenadogene nolparvovec

A Functional Composite Endpoint to Characterize Disease Progression in Patients with Active or Non-active Secondary Progressive Multiple Sclerosis

Ludwig Kappos - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Gray Matter Volume and Myelination Assessed by Magnetization Transfer Ratio Predict Disease Progression in Secondary Progressive Multiple Sclerosis: Exploratory Analyses from the EXPAND Study

Robert J. Fox - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Siponimod

Long-Term (1-Year) Seizure Freedom with Adjunctive Perampanel in Pediatric Patients (Aged 4–<12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Post Hoc Analysis of Study 311

Robert Flamini - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Epilepsy

Perampanel

Long-Term (1-Year) Evaluation of Adjunctive Perampanel on Mental Health in Pediatric Patients (Aged 4−<12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) in Study 311

Rohit Shankar - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Perampanel

Long-term Effect of Siponimod on MRI Outcomes in SPMS: Analyses from the EXPAND Study up to 5 Years

uglas L. Arnold - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Siponimod

Patient Preference for Early Onset of Efficacy in Migraine Prevention

Paul Winner - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Migraine

N/A

Perampanel Monotherapy Beyond Initial Titration to Achieve Seizure Freedom in Patients With Partial-Onset Seizures (POS), With/Without Secondarily Generalized Seizures (SGS): Post Hoc Analysis of Phase III Study 342 (FREEDOM)

Ryan Edbert Husni - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Epilepsy

Perampanel

Perampanel as Early Add-on Therapy for Epilepsy Patients with Focal and Generalized Seizures Treated in Clinical Practice

Estevo Santamarina - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Epilepsy

Perampanel

PROVE Study 506: Analysis of a Retrospective, Phase IV Study of Perampanel in Real-World Clinical Care of Patients Based on Study Site Participation in Previous Clinical Trials

Robert T Wechsler - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Perampanel

Validation of diagnostic criteria for early-stage primary lateral sclerosis: Disease burden in “Probable PLS”

Eoin Finegan - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

RNA interference screening for novel cytokine and chemokine factors regulating HIV-1 trans-infection from dendritic cells to CD4+ T-cells

S. Caucheteux - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Human immunodeficiency virus infection

N/A

Dermis-hair follicle communication: Extracellular microvesicles signaling for hair regeneration

B. Closs - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Becaplermin

Filters

45280 Abstracts